• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对有侵袭性真菌病证据的免疫功能低下患者的管理。

Management of immunocompromised patients with evidence of an invasive mycosis.

作者信息

Walsh T J

机构信息

Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

出版信息

Hematol Oncol Clin North Am. 1993 Oct;7(5):1003-26.

PMID:8226563
Abstract

Invasive fungal infections have emerged as major causes of morbidity and mortality in immunocompromised patients, particularly granulocytopenic and HIV-infected hosts. Diagnosis and treatment of these infections is determined by the type of fungus and the sites of infection. While Candida spp. and Aspergillus spp. are the most common causes of fungal infection in granulocytopenic patients, less common pathogens are emerging as new challenges. This article summarizes current approaches used in the National Cancer Institute's Pediatric Branch for management of invasive fungal infections.

摘要

侵袭性真菌感染已成为免疫功能低下患者发病和死亡的主要原因,尤其是粒细胞减少和感染HIV的宿主。这些感染的诊断和治疗取决于真菌的类型和感染部位。虽然念珠菌属和曲霉属是粒细胞减少患者真菌感染的最常见原因,但不太常见的病原体正成为新的挑战。本文总结了美国国立癌症研究所儿科分部用于管理侵袭性真菌感染的当前方法。

相似文献

1
Management of immunocompromised patients with evidence of an invasive mycosis.对有侵袭性真菌病证据的免疫功能低下患者的管理。
Hematol Oncol Clin North Am. 1993 Oct;7(5):1003-26.
2
The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.严重免疫功能低下患者联合抗真菌治疗的基本原理:经验疗法与循证医学
Curr Opin Infect Dis. 2006 Aug;19(4):380-5. doi: 10.1097/01.qco.0000235166.16421.e5.
3
The immune response to fungal infections.对真菌感染的免疫反应。
Br J Haematol. 2005 Jun;129(5):569-82. doi: 10.1111/j.1365-2141.2005.05397.x.
4
[Drug resistance in the treatment of invasive fungal infections].[侵袭性真菌感染治疗中的耐药性]
Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2607-11.
5
Recent advances in antifungal prevention and treatment.抗真菌预防与治疗的最新进展。
Semin Hematol. 2009 Jul;46(3):212-29. doi: 10.1053/j.seminhematol.2009.03.003.
6
Fungal infections in the immunocompromised host.免疫功能低下宿主的真菌感染
Clin Haematol. 1984 Oct;13(3):599-630.
7
Management of mycoses in surgical patients -- review of the literature.外科患者真菌病的管理——文献综述
Eur J Med Res. 2002 May 31;7(5):200-26.
8
The place for itraconazole in treatment.伊曲康唑在治疗中的地位。
J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i33-i38. doi: 10.1093/jac/dki222.
9
Treatment of fungal and other opportunistic infections in immunocompromised patients.免疫功能低下患者真菌及其他机会性感染的治疗。
Leukemia. 1997 May;11 Suppl 4:S38-9.
10
Current therapeutic approaches to fungal infections in immunocompromised hematological patients.免疫功能低下血液病患者真菌感染的治疗方法现状。
Blood Rev. 2010 Mar;24(2):51-61. doi: 10.1016/j.blre.2009.11.003. Epub 2010 Jan 6.

引用本文的文献

1
antifungal activities of species isolated from soil samples against .从土壤样本中分离出的物种对……的抗真菌活性。
Curr Med Mycol. 2015 Sep;1(3):33-38. doi: 10.18869/acadpub.cmm.1.3.33.
2
In Vitro Evaluation of Enzymatic and Antifungal Activities of Soil-Actinomycetes Isolates and Their Molecular Identification by PCR.土壤放线菌分离株的酶活性和抗真菌活性的体外评估及其PCR分子鉴定
Jundishapur J Microbiol. 2015 May 31;8(5):e14874. doi: 10.5812/jjm.8(5)2015.14874. eCollection 2015 May.
3
Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.
抗真菌药物在儿童中的药代动力学和药效学及其临床意义。
Clin Pharmacokinet. 2014 May;53(5):429-54. doi: 10.1007/s40262-014-0139-0.
4
Comparison of commercial latex agglutination and sandwich enzyme immunoassays with a competitive binding inhibition enzyme immunoassay for detection of antigenemia and antigenuria in a rabbit model of invasive aspergillosis.在侵袭性曲霉病兔模型中,比较商业乳胶凝集试验和夹心酶免疫测定法与竞争性结合抑制酶免疫测定法检测抗原血症和抗原尿的效果。
Clin Diagn Lab Immunol. 2000 May;7(3):477-85. doi: 10.1128/CDLI.7.3.477-485.2000.